spacer
home > ebr > Summer 2019
PUBLICATIONS

European Biopharmaceutical Review

ebr
Summer 2019

   
Text
PDF
bullet
Genomics and DNA
Advancements in Genealogy

The DNA of a New Industry

Futura Genetics’ Efi Binder delves into the rapidly progressing field of genome sequencing, expanding on the decreasing costs that are associated with this type of testing.
 
view
download pdf
bullet
ADCs as Therapeutics
Leveraging Automated Discovery Platforms

Easy as ADC

Dr Xin Liu at Sphere Fluidics emphasises the efficacy and reduced toxicities of novel antibody-drug conjugates as a promising yet costly means to treating life-limiting diseases.
 
view
download pdf
Analytical Techniques in Therapeutics

ADC Characterisation

Christopher M Bianchetti PhD, Henry J Parker, Katherine C Hanson PhD, and Stephen Gacheru PhD at PPD Laboratories illustrate how monoclonal antibody-based therapeutics are advancing cancer treatment.
 
view
download pdf
Antibody-Drug Conjugates in Chemotherapy

The ADC Jigsaw

Antibody-drug conjugates are good contenders in the fight against cancer. Dr Jenny Thirlway at Iksuda outlines how this route of cancer treatment is more effective in eradicating cancer cells and reducing side effects.
 
view
download pdf
bullet
Features
Choosing the Right Biomaterial

A View from the Bench

Barbara Vanhoecke at Rousselot investigates the possibility of removing endotoxins that have proven to be a hindrance in instances where using gelatin would be preferable.
 
view
download pdf
The Cancer Problem

Closer to the Cure

Christian Rommel at Roche advises companies to refrain from treating every step forward in cancer research as a potential cure. Rather, scientists should accept that finding a cure will be a more difficult journey than anticipated.
 
view
download pdf
Immunoncology Drug Development

Do More With Less

Dr Katie Chapple at Sartorius Stedim Biotech and Andrea Gomez-Donart at IntelliCyt outline the current advances in immunoncology, looking specifically at drugs that harness the immune system.
 
view
download pdf
Antibiotic Resistance

Fighting the Global Threat

DAs antibiotic resistance continues to plague the healthcare industry, Adrian Fellows at AGA Nanotech urges companies to unite and educate
 
view
download pdf
Achieving the Full Potential of Immunoncology

Leveraging Novel Therapeutics and Diagnostic Assays

Marisa Pearce at Molecular MD, an ICON company, argues that, although immunotherapy is nothing new, it has much untapped potential yet to be explored.
 
view
download pdf
Translational Safety

The Next Frontier

InSphero’s Judi Wardwell, Dr Radina Kostadinova, and Professor Armin Wolf believe in vitro tissue models to be the way forward in reducing attrition rates of drug candidates, ultimately improving patient safety and return on investment.
 
view
download pdf
Fermenting Peptides and Proteins

The Renaissance of Microbial Fermentation

The advent of cell culture systems ultimately led to increased interest of microbial-produced biopharmaceuticals, as told by Dr Vladas Bumelis at Northway Biotechpharma.

 
view
download pdf
bullet
Analytical Methods
AI and Multifactorial Data Analytics

A New Lens

Analytical tools are necessary for understanding the architecture of multifactorial diseases. Steve Gardner at RowAnalytics introduces the new generation of artificial intelligence and data analytics that can aid in the untangling of disease risk.


 
view
download pdf
Examining Process Residuals

Mass Spectrometric Analysis of Process-Related Impurities

Dr Richard L Easton and Dr Andrew J Reason at BioPharmaSpec demonstrate why mass spectrometry is a highly versatile tool for residual detection, even in the most complex of mixtures.
 
view
download pdf

Neurodegenerative Diseases
Systems Medicine and Drug Repurposing

An Answerable Challenge

Neurodegeneration and neurological disorders as a whole could be considered as the main cause of disability-adjusted years. Dr Hermann Mucke at H.M. Pharma Consultancy encourages the exploration of new drug combinations to drive treatment of such diseases.
 
view
download pdf
Targeting Aβ Oligomers

The Future of R&D in Alzheimer’s Disease

Dr Neil Cashman and Dr James W Kupiec at ProMIS Neurosciences explain the ways in which new investigational drugs are transforming clinical trial design and the R&D landscape.
 
view
download pdf
bullet
Regulars
In Brief

Great Expectations

EBR’s Industry Advisor Emile Bellott reviews rare disease progress in the biopharmaceutical arena.

 
view
download pdf
Immunology

The Factory for Next- Generation Therapies

EBR’s Editor Dr Deborah O’Neil recounts the themes of the issue, warning of the dangers of antimicrobial resistance while celebrating advancements in personal genetic data.
 
view
download pdf
   
spacer


Published quarterly in
January, April,
July, and October

News and Press Releases

Huge boom in Korean Pharma reported at CPhI Korea

Amsterdam, 19th September 2019: The recently-closed CPhI Korea – co-organised by Informa Markets and the Korea Pharmaceutical Traders Association (KPTA) – has seen a surge in growth across domestic and international pharma companies, as well as a sizable rise in overall attendees. As reported earlier this year in the provisional findings of the CPhI Pharma Index[1], Korea has seen a rapid growth in its international reputation (seeing its ‘overall competitiveness’ rise 14% in the last two years), which is now translating into a sizable growth in the market and at the event.
More info >>

White Papers

Backward Thinking

Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market.
More info >>

Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement